ABSTRACT Background Smokeless tobacco (SLT) use is a major global risk factor for oral potentially malignant disorders (OPMDs). However, the differential impact of SLT product composition, particularly tobacco‐only versus combined tobacco‐areca nut products, on OPMD prevalence remains inadequately characterized. Objective To compare the pooled prevalence of OPMDs between users of tobacco‐only SLT and users of SLT containing both tobacco and areca nut. Methods This study was conducted following PRISMA guidelines. Electronic databases (PUBMED, Cochrane, Scopus, Embase, Web of Science) were searched until December 15, 2024. Included studies reported OPMD prevalence among current SLT users with a clear product description. Areca nut‐only products were excluded. Two reviewers independently screened studies, extracted data, and assessed quality (Newcastle‐Ottawa scale). Pooled prevalence estimates were calculated using random‐effects models in R software due to anticipated heterogeneity. Sensitivity analysis (leave‐one‐out) was performed. Results Thirty‐three studies (62 680 SLT users: 5058 tobacco‐only; 57 622 tobacco‐areca nut) were included. Overall OPMD prevalence was significantly higher among SLT with areca nut users (16.3%, 95% CI) compared to tobacco‐only SLT users (10.4%, 95% CI). Tobacco‐areca nut use showed markedly high prevalence of oral submucous fibrosis (OSMF) (33%) and dysplasia (16%), especially in endemic regions like India (88.8% OPMD prevalence in this subgroup). Tobacco‐only SLT use was predominantly associated with leukoplakia (18%) and lichen planus/lichenoid reactions (15%). A critical limitation was the high proportion of non‐specific OPMD diagnoses (27% overall, 38% in tobacco‐areca nut users), hindering precise estimates of specific conditions. Sensitivity analyses confirmed result robustness. Conclusions This meta‐analysis demonstrates a substantial global burden of OPMDs among SLT users, with distinct risk profiles driven by product composition. Tobacco–areca nut SLT poses the highest risk (especially for OSMF and dysplasia), while tobacco‐only SLT remains a significant independent risk factor (primarily for leukoplakia and lichenoid reaction). The high prevalence, particularly with combined products in regions like South Asia, underscores the urgent need for targeted public health interventions. Future research must prioritize precise product classification and standardized OPMD diagnosis to improve risk assessment.
Sivaramakrishnan et al. (Mon,) studied this question.